AOLS (Aeolus Pharmaceuticals) Change In Receivables: $0.43 Mil (TTM As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aeolus Pharmaceuticals Change In Receivables?

Aeolus Pharmaceuticals AOLS Change In Receivables is $0.43 Mil as of Jun. 2017.

Aeolus Pharmaceuticals's change in receivables for the quarter that ended in Jun. 2017 was $0.29 Mil. It means Aeolus Pharmaceuticals's Accounts Receivable declined by $0.29 Mil from Mar. 2017 to Jun. 2017 .

Aeolus Pharmaceuticals's change in receivables for the fiscal year that ended in Sep. 2016 was $0.84 Mil. It means Aeolus Pharmaceuticals's Accounts Receivable declined by $0.84 Mil from Sep. 2015 to Sep. 2016 .

Aeolus Pharmaceuticals's Accounts Receivable for the quarter that ended in Jun. 2017 was $0.31 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aeolus Pharmaceuticals's Days Sales Outstanding for the three months ended in Jun. 2017 was 2,197.02.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aeolus Pharmaceuticals's liquidation value for the three months ended in Jun. 2017 was $0.05 Mil.

Aeolus Pharmaceuticals  (OTCPK:AOLS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aeolus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2017 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.313/0.013*91
=2,197.02

2. In Ben Graham's calculation of liquidation value, Aeolus Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Aeolus Pharmaceuticals's liquidation value for the quarter that ended in Jun. 2017 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.403-0.587+0.75 * 0.313+0.5 * 0
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Change In Receivables Related Terms

Aeolus Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Change In Receivables Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 0.41 -1.19 -0.03 0.84

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 -0.01 0.21 -0.06 0.29

Aeolus Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.43 Mil mean?
Aeolus Pharmaceuticals (AOLS) has a Change In Receivables of $0.43 Mil as of Jun. 2017. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Change In Receivables too high?
Aeolus Pharmaceuticals' current Change In Receivables is $0.43 Mil.
How does Aeolus Pharmaceuticals' Change In Receivables compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Change In Receivables of $0.43 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Change In Receivables is $0.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Change In Receivables of $0.43 Mil. The current Change In Receivables is $0.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Change In Receivables is $0.43 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.